A 6-bromoindirubin-3'-oxime incorporated chitosan-based hydrogel scaffold for potential osteogenic differentiation: Investigation of material properties in vitro.

Autor: Agnes CJ; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada. Electronic address: celine.agnes@mail.mcgill.ca., Murshed M; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada; Shriners Hospital for Children, Montreal, QC, Canada. Electronic address: monzur.murshed@mcgill.ca., Takada A; Institute of Parasitology, McGill University, Montreal, QC, Canada. Electronic address: adrien.takada@mail.mcgill.ca., Willie BM; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada; Shriners Hospital for Children, Montreal, QC, Canada; Department of Pediatric Surgery, McGill University, Montreal, QC, Canada. Electronic address: bwillie@shriners.mcgill.ca., Tabrizian M; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada. Electronic address: maryam.tabrizian@mcgill.ca.
Jazyk: angličtina
Zdroj: International journal of biological macromolecules [Int J Biol Macromol] 2023 Feb 01; Vol. 227, pp. 71-82. Date of Electronic Publication: 2022 Dec 17.
DOI: 10.1016/j.ijbiomac.2022.12.130
Abstrakt: Effective treatments for critical size bone defects remain challenging. 6-Bromoindirubin-3'-Oxime (BIO), a glycogen synthase kinase 3β inhibitor, is a promising alternative for treatment of these defects since it aids in promoting osteogenic differentiation. In this study, BIO is incorporated into a new formulation of the guanosine diphosphate cross-linked chitosan scaffold to promote osteogenic differentiation. BIO incorporation was confirmed with 13 C NMR through a novel concentration dependent peak around 41 ppm. The rapid gelation rate was maintained along with the internal structure's stability. The 10 μM BIO dose supported the control scaffold's microstructure demonstrating a suitable porosity and a low closed pore percentage. While pore sizes of BIO incorporated scaffolds were slightly smaller, pore heterogeneity was maintained. A proof-of-concept study with C2C12 cells suggested a dose-dependent response of BIO on early stages of osteogenic differentiation within the scaffold. These results support future work to examine BIO's role on osteogenic differentiation and biomineralization of encapsulated cells in the scaffold for bone regeneration.
Competing Interests: Declaration of competing interest Maryam Tabrizian on behalf all the authors declares that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: